特罗凯对晚期非小细胞肺癌患者的有效性与安全性

To Investigate the Efficacy and Safety of Tarceva on 24 Patients with Advanced Non-Small Cell Lung Cancer

目的 探讨特罗凯治疗晚期非小细胞肺癌（NSCLC）患者的有效性与安全性方法 收集2015年1月至2016年2月在我院治疗的经病理证实的晚期NSCLC患者24例。给予特罗凯150mg/次,口服,每天1次,直至病情进展或出现严重不良反应而停止治疗。按照RECIST实体瘤疗效评价标准和美国国家癌症研究院（NCI）的毒性评价标准来评价特罗凯的临床疗效和不良反应。结果 24例患者均可评价疗效和毒副作用。疗效方面：完全缓解（CR）0例,部分缓解（PR）4例,疾病稳定（SD）15例,疾病进展（PD）5例,客观有效率16.7%,疾病控制率79.2%,中位无进展生存期（PFS）5.1个月（1.1～13.6个月）,中位生存时间6.4个月（4.3～15.0个月）。常见不良反应有皮疹（83.3%）,多为CTC1、2级,经对症治疗后好转,未出现严重不良反应。结论 特罗凯对晚期非小细胞肺癌疗效明显,安全性好,值得临床使用。

Objective To investigate the clinical efficacy and safety of Tarceva in the treatment of patients with advanced non - small cell lung cancer. Methods 24 cases of advanced non - small cell lung cancer were collected from January, 2015 to February, 2016. All patients were given Tarceva 150mg once daily until disease progress or severe side effect. The efficacy was evaluated accord- ing to Response Evaluation Criterion Solid Tumors （RECIST）criteria, the adverse events were evaluated according to the National Canc- er Institute （NCI） criteria. Results 24 cases could be evaluated in the efficacy and adverse reactions. Four patients got partial re- sponse, fifteen patients got stable disease and five had disease progression. The response rate was 16.7% , the disease control rate was 79.2% , the median progression - free survival time was 5.1 months （ 1.1 - 13.6 months ）, and the median survival time was 6.4 months （4.3 -15.0 months）. The common side effect were skin rash （83.3%） which were almost grade 1 or 2. The patients with side effect got remission by Symptomatic treatment. Conclusion Tarceva therapy is effective and safe for patients with advanced non - small cell lung cancer, so the treatment is worth clinical use.